Publications by authors named "Julia L Moore Vogel"
Article Synopsis
- The publication contained an error regarding the name of the fourteenth author.
- The incorrect name was initially printed in the article.
- The correct name has now been provided to clarify the mistake.
Article Synopsis
- A clinical study was conducted in New York City with 30 glioblastoma patients to compare the effectiveness of whole genome sequencing (WGS) and RNA sequencing (RNA-seq) against targeted panel sequencing in identifying treatment options.
- WGS/RNA-seq uncovered significantly more actionable clinical results—90% of the time—with an average of 16 times more unique variants identified, leading to 84 calls for actionable treatments that targeted panels missed.
- The study found good agreement between manual and automated variant identification, showing that clinicians modified treatment plans based on this data in 10% of cases, marking a significant advancement in cancer treatment analysis.
Article Synopsis
- The study aimed to analyze a glioblastoma tumor specimen using three different methods to identify actionable variants.
- Tumor DNA was assessed through targeted panel analysis, whole-genome sequencing (WGS), and RNA sequencing (RNA-seq), with data evaluated by both human experts and IBM Watson Genomic Analytics (WGA).
- Results showed that WGS and RNA-seq identified more variants than targeted panels, and WGA performed the analysis much faster than human analysts, highlighting the potential for improved patient care with human-machine collaboration.
The DNA content of nuclei is a valuable measure of cell cycle status. Irises is a software tool to facilitate systematic in situ determination of DNA content for cell cycle analysis at single-nucleus resolution within complex tissues. We demonstrate the utility of the tool with analysis of DNA content in germline nuclei of C.
View Article and Find Full Text PDF